BioSpace News Archive

InMode Ltd., a leading global provider of innovative medical technologies, has filed a complaint with the United States International Trade Commission alleging ILOODA’s SecretRF fractional radio frequency microneedling system, distributed in the United States by Cutera, Inc., infringes U.S. Patent No. 10,799,285.

Inflammatix , a pioneering molecular diagnostics company, announced today the closing of a $102 million Series D round of financing to support development and commercialization of its novel immune response diagnostics portfolio. D1 Capital Partners led the round, with participation from the company’s existing investors, including Northpond Ventures, Khosla Ventures, Think.Health, and OSF Healthcare Ventures.

Stealth BioTherapeutics (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced promotion of Marty Redmon , Ph.D., Executive Vice President, Discovery, Development, and Tech Ops, to the role of Chief Research & Development Officer

The Screening Addresses Potential Approaches to Treating Emerging and Future Variants of SARS-CoV-2 Through Multi-Antibody Combination Therapy

VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing and commercializing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (CNS) disorders, today announced that Shawn Singh, VistaGen’s Chief Executive Officer , will participate in the following investor conferences in March:

- IZI Medical Products, LLC (“IZI”), a leading manufacturer of medical devices used in interventional radiology and interventional oncology procedures, announces the launch of its Quick-Core Auto Biopsy System (“Quick-Core Auto”) for soft tissue biopsy. The Quick-Core Auto is a lightweight, fully automatic biopsy device that bu

Diversey Holdings, Ltd. (Diversey), a leading provider of hygiene, infection prevention and cleaning solutions, today announced the launch of its initial public offering of 46,153,846 ordinary shares. Diversey also intends to grant the underwriters a 30-day option to purchase up to an additional 6,923,077 ordinary shares from Diversey. The initial public offering price is currently expected to be between $18.00 and $21.

via InvestorWire – Imagin Medical Inc. reported continued progress towards commercial-stage manufacturing capability with Lighthouse Imaging.

Sensus Healthcare, Inc., a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announced that the first canine patient was successfully treated with the company’s SRT-100™ system.

Merck KGaA, Darmstadt, Germany, a leading science and technology company, announced topline data from the Phase II INTR@PID BTC 047 study evaluating bintrafusp alfa as a monotherapy in the second-line treatment of patients with locally advanced or metastatic biliary tract cancer who have failed or are intolerant of first-line platinum-based chemotherapy.